Neuroendocrine Prostate Cancer Epidemiology Forecast 2026-2035

Neuroendocrine prostate cancer (NEPC) is a rare, aggressive subtype of prostate malignancy. According to Rita Aranha et al., 2025, de novo NEPC accounts for less than 1% of cases, while treatment-emergent NEPC develops in 15-20% of advanced patients. According to neuroendocrine prostate cancer epidemiology forecast, rising therapeutic resistance contributes to increasing global incidence trends.

Neuroendocrine Prostate Cancer Epidemiology Forecast Report Coverage

The analyst's “Neuroendocrine Prostate Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of neuroendocrine prostate cancer. It projects the future incidence and prevalence rates of neuroendocrine prostate cancer cases across various populations. The study covers age, gender, and type as major determinants of the neuroendocrine prostate cancer population. The report highlights patterns in the prevalence of neuroendocrine prostate cancer over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of neuroendocrine prostate cancer in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Neuroendocrine Prostate Cancer Understanding: Disease Overview

Neuroendocrine prostate cancer (NEPC) is a rare, aggressive subtype of prostate cancer characterized by the differentiation of tumor cells into neuroendocrine-like cells. It may arise de novo or develop as a treatment-emergent form following prolonged androgen deprivation therapy in advanced prostate adenocarcinoma. NEPC is associated with low or absent androgen receptor signaling and typically exhibits rapid progression, visceral metastases, and poor prognosis. Histological subtypes include small cell carcinoma, large cell neuroendocrine carcinoma, and mixed adenocarcinoma-neuroendocrine tumors, each with distinct morphology and clinical behavior.

Neuroendocrine Prostate Cancer Epidemiology Perspective

The neuroendocrine prostate cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the neuroendocrine prostate cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for neuroendocrine prostate cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Zdravko Vassilev et al., 2025, neuroendocrine prostate cancer accounted for 0.4% of 607,280 prostate cancer cases in the United States, highlighting its rarity. The median age at diagnosis was 76 years, indicating a strong predominance among elderly patients.
• As per ecancer, approximately 10-15% of patients with metastatic prostate cancer eventually develop neuroendocrine prostate cancer, reflecting its emergence during disease progression and treatment resistance, particularly following prolonged androgen deprivation therapy exposure.
• According to Nastasiia Artamonova et al., 2025, de novo neuroendocrine prostate cancer occurs in less than 2% of cases, while treatment-emergent forms develop in up to 30% of castration-resistant prostate cancer patients, emphasizing increasing incidence in advanced disease stages.
• According to Zdravko Vassilev et al., 2025, 72% of diagnosed patients were white, indicating demographic variation, while gender distribution remains exclusively male due to prostate-specific pathology, reinforcing its unique epidemiological confinement to the male population.
• As per Ziwei Wang et al., 2022, neuroendocrine prostate cancer demonstrates a poor prognosis with an approximate five-year survival rate of 10%, underscoring high mortality and aggressive disease progression compared to conventional prostate adenocarcinoma.

Country-wise Neuroendocrine Prostate Cancer Epidemiology

The neuroendocrine prostate cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the United States, Europe, Japan, and India, the epidemiology of neuroendocrine prostate cancer reflects patterns observed within the broader prostate cancer burden, with regional variability in incidence and survival. According to Carlos A. Cardenas, 2023, the United States reported over 288,300 new prostate cancer cases in 2023, with rising projections, indicating a substantial at-risk population. As per Madeleine J. Karpinski et al., 2025, Western Europe shows high incidence rates, with Germany reporting 72,600 cases in 2019 and incidence rates of 54.2 per 100,000 in 2022, while Italy recorded 49.5 per 100,000. According to Vijay Kumar et al., 2025, India demonstrates lower incidence (5.6 per 100,000) but relatively higher mortality, highlighting regional disparities across the covered markets.

Neuroendocrine Prostate Cancer: Treatment Overview

Treatment of neuroendocrine prostate cancer primarily involves systemic chemotherapy due to its aggressive nature and resistance to hormonal therapies. Platinum-based regimens, such as cisplatin or carboplatin combined with etoposide, are commonly used as first-line therapy. Additional approaches may include taxane-based chemotherapy, immunotherapy in selected cases, and targeted therapies currently under clinical investigation. Radiation therapy may be applied for localized control or palliative management. Given the poor prognosis and limited standard options, enrollment in clinical trials is often recommended to explore emerging therapeutic strategies and improve patient outcomes.

Key Questions Answered

• What are the key findings of neuroendocrine prostate cancer epidemiology in the 8 major markets?
• What will be the total number of patients with neuroendocrine prostate cancer across the 8 major markets during the forecast period?
• What was the country-wise neuroendocrine prostate cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of neuroendocrine prostate cancer patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of neuroendocrine prostate cancer during the forecast period of 2026-2035?
• What are the currently available treatments for neuroendocrine prostate cancer?
• What are the disease risks, signs, symptoms, and unmet needs of neuroendocrine prostate cancer?

Scope of the Neuroendocrine Prostate Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of neuroendocrine prostate cancer based on several factors.
• Neuroendocrine Prostate Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The neuroendocrine prostate cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.